Although the observed incidence of hypophysitis was 3.2% in anti-CTLA-4 antibody, 0.4% in anti-PD-1 antibody, and less than 0.1% in anti-PD-L1 antibody, the incidence was increased to 6.4% in the combination therapy group. This evidence concerns the gene CTLA4 and hypophysitis.